Nuvectis Pharma (NVCT) Insider Charles Buys $916K of Stock
Mosseri Marlio Charles purchased 50,000 shares of Nuvectis Pharma, Inc. at $18.32 each.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mosseri Marlio Charles bought 50,000 shares of Nuvectis Pharma, Inc. ($NVCT) at an average price of $18.32, worth about $916,000, on June 30, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NVCT is up 4.4% after 1 week, up 23.8% after 1 month and up 1.1% to date (from the $18.39 close on Jun 30, 2026).
NVCT
Nuvectis Pharma, Inc.
Key Points
- Mosseri Marlio Charles bought 50,000 shares of Nuvectis Pharma, Inc. (NVCT) at $18.32 per share, totaling $916,000 on June 30, 2026.
- Shares of NVCT traded near $19.46 on Wednesday, with a market cap of approximately $487.8 million and a 52-week range of $5.55 to $29.28.
- Analysts from HC Wainwright & Co. maintained a buy rating with a $39 price target as of June 22, 2026.
Get $NVCT trade alerts by text
We text you when insiders, Congress or big funds trade $NVCT. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Nuvectis Pharma, Inc. alert may contain errors. Disclosures
Mosseri Marlio Charles, an insider at Nuvectis Pharma, Inc. (NasdaqCM: NVCT), purchased 50,000 shares of the company on June 30, 2026. The shares were bought at an average price of $18.32, bringing the total transaction value to $916,000. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Nuvectis Pharma, Inc.
On the same day, Ron Bentsur, the Chairman & CEO, also bought 12,500 shares at $20 each. Earlier in June, several other insiders, including Kenneth Hoberman and Juan Sanchez, acquired 35,000 shares each at undisclosed prices.
Nuvectis Pharma, Inc. Stock Down 11.5%
Shares of Nuvectis Pharma traded near $19.46 on Wednesday. The company has a market cap of approximately $487.8 million. It operates with a forward P/E ratio of -19.16, indicating it is not yet profitable. The stock's beta is -0.072, suggesting lower volatility compared to the market. Over the past year, the stock has ranged from a low of $5.55 to a high of $29.28. Nuvectis has a 50-day moving average of $11.73 and a 200-day moving average of $8.51.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. maintained its buy rating for Nuvectis Pharma, setting a price target of $39. The company has a consensus recommendation of 'strong buy' with a mean price target of $29.20 based on five analyst opinions.
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company based in Fort Lee, New Jersey. It focuses on developing precision medicines for oncology, addressing serious conditions with unmet medical needs. The company is currently working on NXP900, a small molecule drug candidate in Phase 1b trials aimed at treating solid tumors by inhibiting specific kinases. Nuvectis was founded in 2020 and is led by CEO Ron Bentsur.
Bottom Line
Insider buying activity at Nuvectis Pharma, including purchases by Mosseri Marlio Charles, signals confidence in the company's prospects. Investors often watch such transactions as potential indicators of future performance, though it's important to note that insider activity is just one of many factors to consider. The company's stock has shown significant volatility, and analysts remain optimistic with strong buy ratings.
Related Filing Alerts
Source: Mosseri Marlio Charles's Form 4 filing on $NVCT (Jun 30, 2026). Find the original filing: NVCT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts